Dr. Susanna Cooper completed a BSc in Biochemistry at Queen’s University in Canada followed by a MSc in Forensic Science at King’s College London. Following 2 years as a research technician with the CRY Cardiovascular Pathology laboratory, she completed a BHF-sponsored PhD in Cardiovascular Sciences at St. George’s, University of London. Her PhD research was focused on the cardiac impact of kinase inhibitors used as cancer treatments, particularly in the setting of stress such as hypertension. Primarily, she was interested in the concept of the RAF paradox and the development of novel ‘paradox breaking’ inhibitors. Since completion of her PhD in September 2022, Dr. Cooper has started as a Postdoctoral Research Scientist in Professor Paul Riley’s group. As part of a MRC program, she is studying immunomodulation following cardiac injury, with a particular focus on cardiac lymphangiogenesis, to ascertain the optimal local injury environment for tissue repair after a heart attack.